Introduction
============

Bladder cancer is not a rare disease as it is the sixth most common carcinoma in the European Union and the eleventh most common worldwide.[@b1-cmar-11-309] German epidemiological data by the Robert Koch Institute (RKI) indicate a difference in frequency of occurrence between males and females.[@b2-cmar-11-309] Among males, it is the fourth most common carcinoma; however, in females, it is only the tenth most common carcinoma. Histo-logically, over 90% of cases are urothelial cell carcinomas (UCCs). A critical factor for prognosis of the disease is the depth of infiltration. About 75% of first diagnosed UCCs are in a non-muscle invasive state.[@b3-cmar-11-309] Studies with a focus on sex differences in non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) are limited. We examined possible sex-specific differences in histopathological aspects, affiliation with risk groups, and recurrence and progression behaviors. We also investigated whether intravesical chemotherapy (IVC) instillation or initial resection using photodynamic diagnosis (PDD) influenced these factors, in particular, sex-specific factors.

Materials and methods
=====================

Study design and participants
-----------------------------

Patients who underwent transurethral resection of the bladder tumor (TUR-BT) at the Department of Urology and Pediatric Urology at Marburg University Hospital (Germany) between December 2004 and July 2012 were identified. We retrospectively analyzed patient records and created a database for a total of 1,296 interventions. Variables included in the analysis were histopathological findings, TNM, and tumor differentiation, as well as the use of PDD or IVC with Mitomycin C (MMC) 40 mg in between 6 hours after TUR-BT.

Tumor stage, grade, risk group
------------------------------

Tumors were staged using the most recent TNM classification of the Union International Center le Cancer.[@b4-cmar-11-309] We graded tumors according to the WHO's 1973 classification.[@b5-cmar-11-309] Based on the risk group criteria established by the European Association of Urology (EAU), we assigned patients with NMIBC to low, intermediate, and high-risk groups.[@b6-cmar-11-309]

Statistical analyses
--------------------

We analyzed the data in their entirety and by sex using SPSS for Mac Version 22^®^ (IBM Corporation, Armonk, NY, USA). Statistical analyses included Pearson's correlation coefficient, Mann--Whitney U-test, ANOVA, and chi-squared test of independence. We chose to perform a Kaplan--Meier analysis with log-rank tests and a Cox proportional hazards model. Study variables included sample demographics (ie, age, sex and age at first diagnosis), tumor characteristics (ie, histopathology, TNM, WHO grading, and size at first diagnosis, multilocal vs unilocal disease at first diagnosis, and EAU risk group), frequency of recurrence, frequency of tumor progression, frequency of recurrence after IVC, and frequency of recurrence after primary resection with usage of PDD. The significance level was set at *P*\<0.05 for both one and two-tailed tests.

Ethics approval
===============

This study was conducted in accordance with the principles of the Declaration of Helsinksi. Prior to the start of our retrospective evaluation and data collection, the Ethics Committee of the Philipps University Hospital Marburg informed us that no written ethical assessment was necessary due to the character of the examination. The data which we collected from archived patient's files and used in the study, had been anonymized during the process of collection. The requirement for patients' consent was waived by the Ethics Committee of the Philipps University Hospital Marburg.

Results
=======

A total of 729 patients (♀: ♂ 1: 2.8) underwent TUR-BT at the Department of Urology and Pediatric Urology at Marburg University Hospital (Germany) between December 2004 and July 2012. We diagnosed 479 patients with UCC (♀: ♂ 1: 3.6) and excluded 75 patients who presented with a relapse. The mean follow-up period was 70 months.

We identified 404 patients with a first diagnosed UCC, 312 were male, 92 were female (♀:♂ 1: 3.4). MIBC at the time of initial diagnosis was statistically more common among females (25%, n=23) than males (16%, n=50), which corresponded to a female to male ratio (♀:♂) of 1:0.64 (*P*=0.04). In the MIBC group, T3 stage was significantly increased in the female cohort (*P*=0.02).

Since we focused on NMIBC in this work, we excluded patients with MIBC at initial diagnosis (n=73) from further analysis. The first diagnosed NMIBC group (n=331) resulted in 262 male and 69 female patients (♀: ♂ 1:3.8). We retrospectively followed their clinical course over a mean of 70 months. Patients' distribution and distribution of infiltration depths are shown in [Figures 1](#f1-cmar-11-309){ref-type="fig"} and [2](#f2-cmar-11-309){ref-type="fig"}.

Tumor stage, tumor grading, and EAU risk group
----------------------------------------------

The subgroup analysis of NMIBC revealed a significantly higher incidence of carcinoma in situ (CIS) in males (*P*=0.01). In tumor differentiation, a trend toward an increased occurrence of G3 lesions in males was observed (*P*=0.06). There was no association between sex and EAU risk group classification (low *P*=0.85; intermediate *P*=0.72; and high *P*=0.81, [Table 1](#t1-cmar-11-309){ref-type="table"}).

Recurrence and progression
--------------------------

There was no statistically significant relationship between sex and recurrence rates (*P*\>0.05). The small subgroup of female patients in the EAU low-risk group (n=6) showed a trend toward more frequent relapses (*P*=0.076). Furthermore, 14.5% of females (n=10) and 8% of males (n=21) evidenced tumor progression without reaching statistical significance (*P*=0.1). Among female patients, only those classified as EAU low risk showed progression more frequently compared with male patients (*P*=0.03, [Table 1](#t1-cmar-11-309){ref-type="table"}). Again, the small subgroup of only 6 female patients must be emphasized.

We chose to perform a Kaplan--Meier analysis with log-rank tests and a Cox proportional hazards model on recurrence-free survival (RFS) and progression-free survival (PFS). We examined the covariables "age at first diagnosis", "MIBC or NMIBC", and "Patient's sex" ([Table 2](#t2-cmar-11-309){ref-type="table"}). We found for MIBC an HR for progression of 6.5 (95% CI, 1.29--33.2; *P*=0.02) after a median follow-up of 56 months. This was the only result which reached statistical significance. The Kaplan--Meier plots are shown in [Figures 3](#f3-cmar-11-309){ref-type="fig"} and [4](#f4-cmar-11-309){ref-type="fig"}. The log-rank tests showed no statistically significant difference between female and male patients (RFS *P*=0.93/PFS *P*=0.116).

No further statistically significant relationship between sexes, age, and MIBC/NMIBC could be found for RFS and PFS.

IVC and PDD
-----------

In our cohort, 169 patients (134 male and 35 female) received IVC with MMC. PDD was performed during 69 (54 male and 15 female) initial TUR-BTs, whereas 262 (208 male and 54 female) used only white light resection. Patients receiving IVC showed a lower recurrence rate (14.8% vs 21.9%) without reaching statistical significance (*P*=0.06). IVC reduced recurrence from 20.6% to 17.1% in females and from 22.2% to 14.2% in males, though these findings did not reach statistical significance (*P*\>0.05). Resection using PDD reduced the incidence of recurrence from 15.6% to 11.7%. No significant sex differences were found (*P*\>0.05).

Discussion
==========

Data concerning sex differences in UCC are limited. Previous studies have highlighted various sex differences in UCC. Most studies showed that MIBC at first diagnosis is more often found in female sex. In multiple studies, female patients also showed poorer cancer-specific and overall survival.[@b7-cmar-11-309]--[@b10-cmar-11-309] Our work aimed to add to this growing body of research by further clarifying sex-specific differences in NMIBC. In particular, we were interested in recurrence and progression rates of the disease, as well as differences in response to IVC, the efficacy of PDD, and risk stratification according to EAU criteria.

In our cohort, MIBC was significantly more common at the time of the first diagnosis in females (*P*=0.04). Our data are in accordance with other studies like Soave et al examining 517 patients with UCC treated with radical cystectomy.[@b11-cmar-11-309] Similar to our results, they found a higher proportion of female patients with pT2 and pT3 UCC. Shariat et al analyzed the available literature from 1966 to 2009.[@b7-cmar-11-309] In their review, they tried to find theories to explain the higher proportion of male patients who suffered from bladder cancer in general as well as the higher percentage of MIBC in the female sex. One theory is the influence of sex hormones. The review concluded that, so far, no sufficient explanation has been found. Henning et al retrospectively investigated possible sex differences concerning referral patterns in UCC.[@b12-cmar-11-309] They found that female patients tend to have prolonged treatment for urinary tract infection before being referred to a urologist, maybe leading to delayed diagnosis of UCC. Henning et al stated this as a possible explanation for the gender gap in outcomes both in NMIBC and MIBC. Thorstenson et al examined 31,283 patients in Sweden who were followed up in a central registry after initial diagnosis.[@b8-cmar-11-309] There was also a significantly higher incidence of MIBC in the female sex. However, the analysis of Horstmann et al, which found a statistically insignificant increase in MIBC in male patients, should be mentioned. Unfortunately, no explanation for these strongly differing numbers was given.[@b13-cmar-11-309]

We found no significant sex differences in NMIBC concerning EAU risk groups. In a large multicenter retrospective study (n=5,122) by Rieken et al, 12.3% of the patients were stratified to low risk, 45% to intermediate, and 42.7% to high risk.[@b14-cmar-11-309]

By comparison, in our cohort at initial diagnosis according to EAU criteria, 8.2% low, 38% intermediate, and 53.8% high-risk tumors were found.

An explanation for these slightly differing numbers could be regional differences as well as a possible selection bias of the Urology University Hospital Marburg as a supraregional "high-volume" center.

Unfortunately, a separate analysis by sex did not take place in the work of Rieken et al; hence, a further comparison is impossible. Even after extensive literature research, no work could be identified, which explored EAU, European Organization for Research and Treatment of Cancer (EORTC), or Spanish Urological Club for Oncological Treatment (CUETO) risk group classification by sex. In our study, there was no significant correlation between sex and risk group classification. Based on our data, we can state first that sex is not associated with the risk profile of newly diagnosed NMIBC.

A fundamental issue in the therapy of NMIBC is the prevention of recurrence. Previous data have not provided consistent recurrence rates. In our sample, 18% of patients developed UCC recurrence over the follow-up period of 70 months. In contrast, Xylinas et al compared the effectiveness of risk stratification according to EORTC and CUETO in a sample of 4,689 patients.[@b15-cmar-11-309] At a median follow-up of 57 months, 45% of patients had relapsed. Walczak et al found a similar relapse rate in their sample of 243 patients over a follow-up period of 46 months (ie, 41% relapses).[@b16-cmar-11-309] In their meta-analysis of seven EORTC studies (n=2,596), Sylvester et al established a relapse rate of 47.8%.[@b17-cmar-11-309] The investigations of the CUETO showed a recurrence rate of 33.5%.[@b15-cmar-11-309] The discrepancy of data may be associated with the inclusion criteria of the current study. We only included patients who presented with an initial diagnosis of UCC as they showed an increased risk of disease recurrence and excluded those who had already relapsed. Another possible explanation for the relatively low proportion of relapses is an improvement in diagnosis, advances in therapy, an increase in resection quality, and the influence of the now regularly performed Re-TURBT.

We further investigated whether belonging to an EAU risk group increased the likelihood of relapse among the entire sample and by sex and could not demonstrate statistically significant relationships (18.8% females vs 18.1% males). Females in our low-risk group showed a recurrence in 50% of cases, but only a trend can be discussed, and the subsample size (n=6) was rather small. In our cohort, we found no signifi-cant sex differences in recurrence rate and RFS in NMIBC.

Another challenge in the treatment of NMIBC is the identification of patients at risk for disease progression. Previous studies showed considerable differences in disease progression rates. In our cohort, 9.4% (n=31) progressed. In contrast, other studies reported progression rates of 10.7%--18%, some of which had been defined differently. For instance, Sylvester et al reported a progression rate of 10.7% into a muscle-invasive stage in a large patient population (n= 2,596). Other groups define progression as histopathological progression to a more advanced stage. Data about sex differences concerning NMIBC progression and time to progression are rare. In our cohort, 14.5% of females and 8% of males developed disease progression (*P*=0.1). However, featuring the NMIBC EAU risk groups, we found that females in the low-risk group showed a significantly higher incidence of disease progression, although the subsample size (n=6) was, again, rather small (*P*=0.03). These results could be accidental. It would be of interest to further explore this finding using a larger patient sample. Furthermore, we found no sex differences concerning PFS in our cohort.

In our study, IVC was not significantly associated with recurrence rates among the entire sample and by sex. Specifi-cally, of the 169 patients who received IVC, 14.8% relapsed. In contrast, 21.9% of the 160 patients who did not receive IVC, relapsed. Compared to other studies, our recurrence rates are relatively low. Malmström et al reported a 43.4% disease recurrence in their sample of 2,820 patients after IVC; however, the study did not include a control group.[@b18-cmar-11-309] Solsona et al examined the effect of IVC in a sample of 131 low-risk NMIBC observing a non-significant decrease in relapse rates (40.3% vs 51.9%).[@b19-cmar-11-309] Again, a possible explanation for the relatively low proportion of relapses in our cohort may be an improvement in the diagnosis, advances of therapy, and an increase in resection quality.

In female and male patients, IVC reduced recurrence rate not significantly (female 17.1% vs 20.6%, male 14.2% vs 22.2%). Given that the subgroup sizes were rather small, it is unclear if our findings are secondary to a genuine lack of association or a lack of power. To date, there are no data available that examined sex-specific relapse rates after IVC. Further prospective and randomized studies are needed to clarify possible differences.

Furthermore, we could not determine a significant difference in the progression rate if using IVC (7.1% vs 11.9%, *P*=0.1) and no sex differences. Perlis et al performed a meta-analysis on the controversial issue of progression risk reduction through IVC.[@b20-cmar-11-309] They conclude, due to the weak data and biased study situations, the evidence regarding statements on IVC and progression risk reduction is "very low".

Our examination of relapse rates when PDD was used during the initial TUR-BT did not yield any significant results among the entire sample and by sex. Specifically, when TUR-BT was performed in conjunction with PDD, 11.7% of patients relapsed compared with 15.6% when PDD was not used. Neither female nor male patients' usage of PDD reduced the recurrence rate significantly (female 13.3% vs 20.3%, male 13% vs 19.2%) also without sex differences. No publications could be found in the literature, which examined sex-differences in relapse rates with use of PDD to compare our findings. However, in concordance with our findings, O'Brien et al similarly did not find an association between PDD use and a decrease in recurrence rates after 12 months.[@b21-cmar-11-309]

In our cohort, we found no significant difference concerning NMIBC progression when using PDD. Furthermore, no sex differences were evident when using PDD. Comparing our results with a meta-analysis on PDD-assisted TUR-BT by Rink et al, a similar picture emerges.[@b22-cmar-11-309] This research showed no evidence for a lower rate of progression in PDD-treated patients. It also addressed the aforementioned difficulties of small subsamples, the problems of various biases, as well as different definitions of "progression", and different primary endpoints.

Conclusion
==========

We can show that female patients are significantly more likely to have MIBC at the time of initial diagnosis, especially tumors with the tumor infiltration depth pT3. In NMIBC, males showed a significantly higher prevalence of CIS. Neither sex exhibited more frequent recurrences. Only the female NMIBC low-risk group showed a significantly increased progression rate. PDD and IVC were equally effective in both sexes, without showing significant sex-specific differences. Our data are encouraging to elucidate possible sex differences in UCC with therapeutical impact. Due to limited data, further prospective and multicenter studies should also be performed focusing on possible causalities.
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![Flowchart of patient selection.\
**Abbreviations:** EAU, European Association of Urology; MIBC, muscle invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer; UCC, urothelial cell cancer; TUR-BT, transurethral resection of the bladder tumor.](cmar-11-309Fig1){#f1-cmar-11-309}

![Distribution of UCC depth of infiltration on first diagnosis.\
**Abbreviation:** UCC, urothelial cell carcinoma.](cmar-11-309Fig2){#f2-cmar-11-309}

![Kaplan--Meier plots for recurrence-free survival.\
**Note:** Probability of recurrence-free survival is plotted over time and the Kaplan--Meier plots indicate no difference in female and male patients (log-rank test *P*=0.93).](cmar-11-309Fig3){#f3-cmar-11-309}

![Kaplan--Meier plots for progression-free survival.\
**Note:** Probability of progression-free survival is plotted over time and the Kaplan--Meier plots indicate no difference in female and male patients. (Log-rank test *P*=0.116).](cmar-11-309Fig4){#f4-cmar-11-309}

###### 

Risk group subgroup analysis

  EAU risk groups   Sex (no.)     Recurrence no. (%)   Risk group specific *P* (χ^2^)   Progression no. (%)   Risk group specific *P* (χ^2^)
  ----------------- ------------- -------------------- -------------------------------- --------------------- --------------------------------
  "Low"                                                0.1                                                    0.03
                    Male (21)     3 (14.3)                                              1 (4.8)               
                    Female (6)    3 (50)                                                3 (50)                
                    Total (27)    6 (22.2)                                              4 (14.8)              
  "Intermediate"                                       1                                                      1
                    Male (101)    18 (17.8)                                             10 (10)               
                    Female (25)   4 (16)                                                2 (8)                 
                    Total (126)   22 (17.5)                                             12 (17.5)             
  "High"                                               0.81                                                   0.32
                    Male (140)    26 (18.6)                                             10 (10.1)             
                    Female (38)   6 (15.8)                                              5 (13.1)              
                    Total (178)   32 (18)                                               15 (8.4)              

**Abbreviation:** EAU, European Association of Urology.

###### 

Cox proportional hazards model for RFS and PFS

        Variables       *P*-value   HR (95% CI)
  ----- --------------- ----------- ----------------------
        Age             0.46        0.991 (0.967--1.015)
  RFS   Patient's sex   0.76        0.907 (0.486--1.694)
        NMIBC           0.35        0.637 (0.25--1.627)
        MIBC            0.06        3.1 (0.955--10.07)
        Age             0.77        1.005 (0.97--1.043)
  PFS   Patient's sex   0.11        0.53 (0.144--1.151)
        NMIBC           0.49        0.597 (0.136--2.615)
        MIBC            0.02        6.54 (1.29--33.2)

**Note:** Two-sided *P*-values were derived from the Cox proportional hazards model using all variables in the table.

**Abbreviations:** HR, hazard ratio; MIBC, muscle invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer; PFS, progression-free survival; RFS, recurrence-free survival.
